French-Thai vaccine biotech group BioNet and PT Bio Farma (Persero), Indonesia's state-owned vaccine manufacturer, have signed a Memorandum of Understanding (MoU) to partner on development and regional distribution of a combined TdaP vaccine (tetanus, diphtheria, and acellular recombinant pertussis).

Signed during the State Visit of French President Emmanuel Macron to Indonesia, the agreement underscores a commitment to accelerating access to innovative vaccines across Southeast Asia. The partnership combines BioNet's proprietary recombinant pertussis technology and global clinical experience with Bio Farma's large-scale manufacturing and public health reach, to address critical immunisation needs in ASEAN.

The MoU outlines cooperation in clinical development, regulatory alignment, and market access. Bio Farma will lead clinical trials and regulatory submissions in Indonesia, while BioNet is responsible for other ASEAN countries. The collaboration aims to reduce vaccine introduction from 10-15 years to less than five.

The TdaP vaccine combines Bio Farma's Td and BioNet's aP antigens. It targets the ASEAN market with an estimated 10-15 million doses annually, valued at around USD200m.